Activated recombinant factor VII for bleeding after a kidney transplant: reflections
Pajares, A.; Larrea, L.
Revista Espanola de Anestesiologia y Reanimacion 53(4): 266-7; author reply 268
2006
ISSN/ISBN: 0034-9356 PMID: 16711505 Document Number: 604967
Document emailed within 1 workday
Related Documents
Beltrán de Heredia, S.; Bisbe, E.; Rojo, A.; Gracia, M.P.; López, M.; Escolano, F. 2008: Usefulness of activated recombinant factor VII for controlling massive bleeding: 4 years' experience in a university hospital Revista Espanola de Anestesiologia y Reanimacion 55(6): 355-359Skalski, J.H.; Czapla, J.; Nadziakiewicz, Pł.; Kaczmarski, J.; Zembala, M. 2002: New possibilities in the postoperative measures to prevent bleeding in cardiac surgery. Will the recombinant activated factor VII improve surgical results? Przeglad Lekarski 59(11): 941-945
Jirapinyo, M.; Manonai, J.; Herabutya, Y.; Chuncharunee, S. 2007: Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review Journal of the Medical Association of Thailand 90(5): 977-981
Charbonneau, S.; Girard, Fçois.; Boudreault, D.; Ruel, M.; Blais, N.; Hardy, J-François. 2007: Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding Thrombosis and Haemostasis 97(2): 296-303
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
Grochova, M.; Kalnasova, B.; Firment, J.; Olejarova, I.; Roland, R.; Lazurova, I. 2011: Pulmonary administration of activated recombinant factor VIi Bratislavske Lekarske Listy 112(1): 29-33
Ingerslev, J.; Thykjaer, H.; Kudsk Jensen, O.; Fredberg, U. 1998: Home treatment with recombinant activated factor VII: results from one centre Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S107-S110
Grinţescu, I.; Tulbure, D.; Mirea, L. 2006: Activated recombinant factor VIi (Novoseven) in multiple trauma patients: an outcome analysis Chirurgia 101(6): 615-624
Koda, N.; Oda, T.; Yokoyama, M.; Matsumoto, A.; Takeuchi, M. 1990: Reactivity of peripheral blood lymphocytes to recombinant interleukin-2 in kidney transplant recipients Transplantation Proceedings 22(5): 2373-2375
Guillet, B.; Pinganaud, C.; Proulle, V.; Dreyfus, M.; Lambert, T. 2002: Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VIi Thrombosis and Haemostasis 88(4): 698-699
Galstian, G.M.; Kolosova, I.V. 2014: Using recombinant activated blood coagulation factor VIi for treatment of hemorrhagic syndrome in patients with thrombocytopenia Anesteziologiia i Reanimatologiia 59(6): 60-66
Radeschi, G.; Boris, E.F.; Sega, P.; Odetto, L.; Venturino, S. 2007: Utilization of recombinant activated factor VIi in a case of spontaneous massive haemothorax in a patient with Von Recklinghausen's disease Minerva Anestesiologica 73(4): 241-244
Seidlová, D.; Blatný, J.; Penka, M.; Ovesná, P.; Brabec, P.; Sevcík, P.; Ventruba, P.; Cerný, V. 2010: Recombinant activated factor VIi in the treatment of life threatening post-partum haemorrhage; registry UniSeven in the Czech Republic Ceska Gynekologie 75(4): 297-305
Vyhovs'ka, I.I.; Karol', I.S.; Fedak, L.M.; Tsytsyk, O.I. 2004: Use of recombinant activated factor VIi (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage Likars'ka Sprava 7: 77-81
Rostaing, L.; Izopet, J.; Baron, E.; Duffaut, M.; Puel, J.; Durand, D. 1995: Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects Transplantation Proceedings 27(1): 948-950
Seligsohn, U.; Modan, M. 1981: Definition of the population at risk of bleeding due to factor Xi deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection Israel Journal of Medical Sciences 17(6): 413-415
Tanchev, S.; Platikanov, V.; Markova, S.; Slavov, N.; Bogdanova, A.; Dimitrova, D. 2004: Use of recombinant factor VIIa for the control of massive bleeding caused by uterine hypotonia in post-placental period Akusherstvo i Ginekologiia 43(1): 16-20
He, W.J.; Hu, Y.; Zhang, X.P.; Hong, M.; Guo, T.; Wei, W.N.; Song, S.J. 2008: Activated protein C ratio, plasma tissue factor activity and activated factor VIi in Chinese patients with coronary heart disease European Journal of Medical Research 13(2): 47-51
Devecioğlu, O.; Unüvar, A.şe.ül.; Anak, S.; Bilge, I.; Ander, H.; Ziylan, O. 2003: Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VIi and platelet transfusions Turkish Journal of Pediatrics 45(1): 64-66
Kącka, K.; Kącki, W.; Merak, J.; Błęka, A. 2010: Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report Ortopedia, Traumatologia, Rehabilitacja 12(5): 448-458